Discovering Gene Expression Signatures Responding to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia

BMC Medical Genomics - United Kingdom
doi 10.1186/s12920-016-0194-5
Full Text
Abstract

Available in full text

Categories
Genetics
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia

Oncology and Therapy
Oncology
2019English

Managing Chronic Myeloid Leukemia Patients Intolerant to Tyrosine Kinase Inhibitor Therapy

Blood Cancer Journal
OncologyHematology
2012English

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia

Molecular Therapy - Nucleic Acids
Drug DiscoveryMolecular Medicine
2017English

Planned Pregnancy in Female Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

Oncologist
Cancer ResearchMedicineOncology
2019English

Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2010English

Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2019English

Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

International Journal of Clinical Pharmacology & Pharmacotherapy
2018English

Effect of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia (Cytogenetic, Molecular Response) in Mosul

Annals of the College of Medicine, Mosul
2018English

Leukemia Stem Cell Gene Expression Signatures Contribute to Acute Myeloid Leukemia Risk Stratification

Haematologica
Hematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy